France Biotechnology Market Size & Outlook, 2024-2030
The biotechnology market in France is expected to reach a projected revenue of US$ 129,455.3 million by 2030. A compound annual growth rate of 12.6% is expected of France biotechnology market from 2024 to 2030.
AstraZeneca PLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Sanofi SA, Biogen Inc, Abbott Laboratories, Pfizer Inc, Amgen Inc, Novo Nordisk A/S ADR, Merck KGaA, Johnson & Johnson, Novartis AG ADR, Roche Holding AG, Lonza Group Ltd
Other key industry trends
In terms of revenue, France accounted for 3.6% of the global biotechnology market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, Germany biotechnology market is projected to lead the regional market in terms of revenue in 2030.
UK is the fastest growing regional market in Europe and is projected to reach USD 227,707.0 million by 2030.
The national biotechnology sector of France is continuously growing with the emergence of start-up companies across the country. With increasing number of start-up companies, the French biotech sector outlined the country's hospitals, universities, and research institutions.
Furthermore, increasing funding from government as well as private sectors is supporting the country's market growth. According to PANORAMA FRANCE HEALTHTECH, in 2019, France ranked first in Europe in terms of number of trials in progress and ranks fourth in Phase I trials.
The same report states that increase in incidence of chronic diseases, population aging, rise in health expenditure, and integration of patient-centered digital tools are some of the trends driving the market growth.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biotechnology Market Outlook will help companies and investors design strategic landscapes.
Health was the largest segment with a revenue share of 44.36% in 2023.
Horizon Databook has segmented the France biotechnology market based on health, food & agriculture, natural reseources & environment, industrial processing, bioinformatics, others applications covering the revenue growth of each sub-segment from 2018 to 2030.
The national biotechnology sector of France is continuously growing with the emergence of start-up companies across the country. With increasing number of start-up companies, the French biotech sector outlined the country's hospitals, universities, and research institutions.
Furthermore, increasing funding from government as well as private sectors is supporting the country's market growth. According to PANORAMA FRANCE HEALTHTECH, in 2019, France ranked first in Europe in terms of number of trials in progress and ranks fourth in Phase I trials.
The same report states that increase in incidence of chronic diseases, population aging, rise in health expenditure, and integration of patient-centered digital tools are some of the trends driving the market growth.
France Biotechnology Market Technology Outlook (Revenue, USD Million , 2018-2030)
Fermentation
Chromatography Market
DNA Sequencing
Cell Based Assay
Others
PCR Technology
Nanobiotechnology
Tissue engineering and Regeneration
France Biotechnology Market Application Outlook (Revenue, USD Million , 2018-2030)
Natural reseources & Environment
Others Applications
Food & Agriculture
Health
Industrial Processing
Bioinformatics
Reasons to subscribe to Biotechnology Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biotechnology Market Outlook databook
Our clientele includes a mix of Biotechnology Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Biotechnology Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Biotechnology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.